What do systematic reviews say?

Fluoxetine vs ABT‐200

• Fluoxetine versus other types of pharmacotherapy for depression 2013 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 141 participants
  Low

Fluoxetine vs mianserin

It is very uncertain whether fluoxetine changes failure to complete ‐ side effects ‐ compared with mianserin (very low certainty).

• Fluoxetine versus other types of pharmacotherapy for depression 2013 · Cochrane Headline outcomes only
  OR 1.05 [0.23, 4.7]
  1 study · 53 participants
  Very low

Fluoxetine vs milnacipran

Fluoxetine showed no clear difference in failure to respond (reduction ≥ 50% on HDRS) compared with milnacipran (moderate certainty).

• Fluoxetine versus other types of pharmacotherapy for depression 2013 · Cochrane Headline outcomes only
  OR 1.2 [0.78, 1.84]
  2 studies · 370 participants
  Moderate

Fluoxetine vs milnacipran

• Fluoxetine versus other types of pharmacotherapy for depression 2013 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 213 participants
  Moderate

Fluoxetine vs milnacipran

Fluoxetine showed no clear difference in failure to complete ‐ total ‐ compared with milnacipran (moderate certainty).

• Fluoxetine versus other types of pharmacotherapy for depression 2013 · Cochrane Headline outcomes only
  OR 0.98 [0.68, 1.42]
  3 studies · 560 participants
  Moderate

Fluoxetine vs milnacipran

Fluoxetine showed no clear difference in failure to complete ‐ inefficacy ‐ compared with milnacipran (moderate certainty).

• Fluoxetine versus other types of pharmacotherapy for depression 2013 · Cochrane Headline outcomes only
  OR 1.25 [0.68, 2.3]
  3 studies · 560 participants
  Moderate

Fluoxetine vs milnacipran

Fluoxetine showed no clear difference in failure to complete ‐ side effects ‐ compared with milnacipran (moderate certainty).

• Fluoxetine versus other types of pharmacotherapy for depression 2013 · Cochrane Headline outcomes only
  OR 1.5 [0.81, 2.76]
  3 studies · 560 participants
  Moderate

Fluoxetine vs mirtazapine

Fluoxetine probably leads to higher failure to respond (reduction ≥ 50% on HDRS) compared with mirtazapine (moderate certainty).

• Fluoxetine versus other types of pharmacotherapy for depression 2013 · Cochrane Headline outcomes only
  OR 1.46 [1.04, 2.04]
  4 studies · 600 participants
  Moderate

Fluoxetine vs mirtazapine

• Fluoxetine versus other types of pharmacotherapy for depression 2013 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 31 participants
  Very low

Fluoxetine vs mirtazapine

Fluoxetine showed no clear difference in failure to complete ‐ total ‐ compared with mirtazapine (moderate certainty).

• Fluoxetine versus other types of pharmacotherapy for depression 2013 · Cochrane Headline outcomes only
  OR 0.9 [0.55, 1.47]
  3 studies · 301 participants
  Moderate

Fluoxetine vs mirtazapine

Fluoxetine showed no clear difference in failure to complete ‐ inefficacy ‐ compared with mirtazapine (moderate certainty).

• Fluoxetine versus other types of pharmacotherapy for depression 2013 · Cochrane Headline outcomes only
  OR 1.45 [0.71, 2.96]
  4 studies · 600 participants
  Moderate

Fluoxetine vs ABT‐200

Fluoxetine may leads to lower failure to complete ‐ total ‐ compared with ABT‐200 (low certainty).

• Fluoxetine versus other types of pharmacotherapy for depression 2013 · Cochrane Headline outcomes only
  OR 0.18 [0.08, 0.39]
  1 study · 144 participants
  Low

Fluoxetine vs mirtazapine

Fluoxetine showed no clear difference in failure to complete ‐ side effects ‐ compared with mirtazapine (moderate certainty).

• Fluoxetine versus other types of pharmacotherapy for depression 2013 · Cochrane Headline outcomes only
  OR 0.95 [0.55, 1.64]
  4 studies · 600 participants
  Moderate

Fluoxetine vs moclobemide

Fluoxetine showed no clear difference in failure to respond (reduction ≥ 50% on HDRS) compared with moclobemide (moderate certainty).

• Fluoxetine versus other types of pharmacotherapy for depression 2013 · Cochrane Headline outcomes only
  OR 1.27 [0.92, 1.75]
  7 studies · 721 participants
  Moderate

Fluoxetine vs moclobemide

• Fluoxetine versus other types of pharmacotherapy for depression 2013 · Cochrane Headline outcomes only
  no estimate extracted
  6 studies · 540 participants
  Moderate

Fluoxetine vs moclobemide

Fluoxetine showed no clear difference in failure to complete ‐ total ‐ compared with moclobemide (moderate certainty).

• Fluoxetine versus other types of pharmacotherapy for depression 2013 · Cochrane Headline outcomes only
  OR 1.01 [0.7, 1.45]
  7 studies · 721 participants
  Moderate

Fluoxetine vs moclobemide

Fluoxetine showed no clear difference in failure to complete ‐ inefficacy ‐ compared with moclobemide (moderate certainty).

• Fluoxetine versus other types of pharmacotherapy for depression 2013 · Cochrane Headline outcomes only
  OR 0.7 [0.32, 1.56]
  6 studies · 679 participants
  Moderate

Fluoxetine vs moclobemide

Fluoxetine showed no clear difference in failure to complete ‐ side effects ‐ compared with moclobemide (moderate certainty).

• Fluoxetine versus other types of pharmacotherapy for depression 2013 · Cochrane Headline outcomes only
  OR 1.07 [0.64, 1.8]
  7 studies · 721 participants
  Moderate

Fluoxetine vs nefazodone

• Fluoxetine versus other types of pharmacotherapy for depression 2013 · Cochrane Headline outcomes only
  no estimate extracted
  0 studies · 0 participants
  GRADE not reported

Fluoxetine vs nefazodone

• Fluoxetine versus other types of pharmacotherapy for depression 2013 · Cochrane Headline outcomes only
  no estimate extracted
  4 studies · 271 participants
  Moderate